Sign in

You're signed outSign in or to get full access.

Patricia Fontneau

Director at InnovAge Holding
Board

About Patricia Fontneau

Independent director (Class III) at InnovAge Holding Corp. since March 2023; age 63 as of October 14, 2025. Former CEO of Colorado’s public health insurance marketplace (Connect for Health Colorado) and senior executive at Cigna, with deep payor-side, regulatory, and risk management expertise; currently CEO of Reach Out and Read Colorado. Education: BS in Business Administration (SUNY Oswego) and MBA in Finance (NYU). Tenure on INNV Board: March 2023–present .

Past Roles

OrganizationRoleTenureCommittees/Impact
CignaPresident, Benefit and Exchange Technology Solutions health plan business2014–2022Led payor-side technology and exchange operations; regulatory oversight and risk management experience .
Connect for Health ColoradoChief Executive Officer2011–2014Ran a public health insurance marketplace; extensive state regulatory engagement .
Holme Roberts & Owen LLPOperations lead2008–2011Managed operations of international law firm .

External Roles

OrganizationRoleTenureNotes
Reach Out and Read ColoradoChief Executive OfficerAug 2022–presentNonprofit leadership (early literacy) .
Downtown Denver PartnershipBoard memberNot disclosedCivic/economic development board service .
International Women’s Forum of ColoradoBoard memberNot disclosedNonprofit board service .

Board Governance

  • Committee assignments: Chair, Quality and Compliance Committee; not on Audit or Compensation & Nominating .
  • Independence: Board determined Ms. Fontneau is independent under Nasdaq rules .
  • Attendance and engagement: FY2025 Board met 4 times; Q&C Committee met 3 times; each director attended ≥75% of meetings except the Chair (Carlson) at 71%—thus Ms. Fontneau met attendance expectations. All directors in office attended the Dec 5, 2024 annual meeting .
  • Controlled company: InnovAge is a Nasdaq “controlled company” and relies on certain governance exemptions (e.g., majority-independent Board not required), which can reduce minority shareholder protections .
  • Committee focus: As Q&C Chair, oversees healthcare compliance risk, investigations of policy breaches, and regulatory program effectiveness; coordinates with management on significant compliance risks and complaints intake processes .

Board Committees and Roles

CommitteeMembershipRoleFY2025 Meetings
Quality & ComplianceMemberChair3
AuditNot a member6 (committee total)
Compensation & NominatingNot a member3 (committee total)

Fixed Compensation (Director)

ComponentFY2025 Amount (USD)Notes
Annual Board retainer (cash)$100,000Paid quarterly to non-employee directors .
Committee chair fee (cash)$20,000Additional annual cash for committee chairs .
Total cash fees$120,000FY2025 director compensation table .

Performance Compensation (Director)

Award TypeGrant DateFair Value (USD)VestingTerms/Notes
RSUs (annual director grant)Sep 3, 2024$100,000Fully vested Mar 29, 2025Time-based; settled in INNV common stock .

Directors do not receive performance-based awards tied to operational or TSR metrics; equity awards are time-based RSUs with fixed vesting schedules .

Other Directorships & Interlocks

Company/OrganizationTypeRoleDatesNotes
Public company boardsPublicNone disclosedNo public company board service listed in INNV proxy biography .
Downtown Denver PartnershipNonprofitBoard memberNot disclosedCivic board .
International Women’s Forum of ColoradoNonprofitBoard memberNot disclosedLeadership network .

Expertise & Qualifications

  • Payor-side executive leadership (Cigna), public exchange operations (Connect for Health Colorado), and nonprofit CEO—strong regulatory and compliance orientation .
  • Risk management and oversight competencies emphasized by the Board in her biography .
  • Formal finance training (MBA in Finance, NYU) .

Equity Ownership

MetricValue
Shares beneficially owned36,809
Ownership as % of shares outstanding<1% (Company’s table denotes “*”)
Unvested RSUs at FY2025 year-endNone disclosed for Ms. Fontneau; her FY2025 RSUs were fully vested by Mar 29, 2025 .
Hedging/pledgingProhibited by INNV Insider Trading Policy (no margin or pledging) .

Insider Trades

DateForm 4 TransactionSharesPriceNotes
FY2025Not disclosed in proxySection 16(a) compliance noted; no delinquency mentioned for Ms. Fontneau (delinquencies cited only for J. Carlson and N. D’Amato) .

Governance Assessment

  • Strengths
    • Independent director and Chair of Quality & Compliance—aligned with InnovAge’s regulatory risk profile; clear oversight responsibilities for compliance violations, quality programs, and complaints processes .
    • Meets attendance expectations and participated in annual meeting; signals engagement .
    • Time-based equity and reasonable cash retainer/chair fee suggest standard director pay structure, with no complex performance metrics that could misalign oversight incentives .
    • Company policy bans hedging/pledging, supporting ownership alignment and risk discipline .
  • Watch items / RED FLAGS
    • Controlled company status and reliance on Nasdaq exemptions reduce minority shareholder protections; sponsors retain nomination and committee seat rights, potentially diluting independent oversight (including on committees alongside sponsor-affiliated directors) .
    • Quality & Compliance Committee includes sponsor-affiliated members; while chaired by an independent, this mixed composition warrants monitoring for potential influence over compliance priorities .
    • No disclosed director-specific ownership guidelines or pledging compliance metrics; beneficial ownership is modest (<1%), though hedging/pledging is prohibited .

Citations: